Prostate-specific Membrane Antigen (PSMA) expression in endometrial cancer

• Conditions: C54; Malignant neoplasm of corpus uteri

• Registration Number: DRKS00025005
• Lead Sponsor: niversitätsklinikum Freiburg Klinik für Frauenheilkunde

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-04-07
• Study Completion: 2021-04-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 61

Inclusion Criteria

Patients with histologically verified invasive endometrial carcinoma are included in this study.

Exclusion Criteria

- no declaration of consent
- other oncological disease
- intake of selective oestrogen receptor modulators (SERM, for example tamoxifen)
- after ovarian stimulation therapy
- histologically proved sarcoma, neuroendocrine tumour or mixed tumour
- cytostatic or radiotherapy administered before tissue sampling

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Description of the PSMA Expression within the endometrium and endometrial carcinoma on previously removed tissue, using immunohistochemistry and immunofluorescence, as well as proteomic analyses if necessary.

Secondary Outcome Measures

Name	Time	Method
Depending on PSMA status (both tumour cells and tumour neovasculature):<br>Survival<br>Disease free survival (dfs).<br>Clinical parameters:<br>Age at time of diagnosis, menopausal status, FIGO stage at time of diagnosis, distant metastasis, body-mass index, use of hormone replacement therapy, family history, Number of births, postoperative radio- or chemotherapy.<br>Histopathological parameters:<br>pTNM stage, histological subtype (endometrioid, mucinous), grading, lymphatic, venous and perineural sheath infiltration, myometrical depth of invasion, three-dimensional tumour size in centimetres, hormone receptor status.